VJVirtual | Development of TCR-NK cell therapy

Namir Hassan, PhD, Zelluna Immunotherapy, Oslo, Norway, discusses the collaboration between Lion TCR and Zelluna to develop an allogeneic T-cell receptor natural killer (TCR-NK) cells for the treatment of virally induced cancers. Dr Hassan also discusses the importance of focusing on the development of TCR-NK cell therapy in targeting hepatitis B virus (HBV) induced liver cancer. Furthermore, Dr Hassan mentions potential collaborations in developing TCRs against other solid indications. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).